Cargando…

Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma

SIMPLE SUMMARY: Anal squamous cell carcinoma (SCC) is a rare cancer often caused by infection with high-risk human papillomavirus (HPV). Immune checkpoint blockade (ICB) targeting PD-1 or PD-L1 is successfully used for the treatment of other cancers as melanoma and lung cancer and might be an option...

Descripción completa

Detalles Bibliográficos
Autores principales: Wessely, Anja, Heppt, Markus V., Kammerbauer, Claudia, Steeb, Theresa, Kirchner, Thomas, Flaig, Michael J., French, Lars E., Berking, Carola, Schmoeckel, Elisa, Reinholz, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564961/
https://www.ncbi.nlm.nih.gov/pubmed/32899762
http://dx.doi.org/10.3390/cancers12092516
_version_ 1783595831564173312
author Wessely, Anja
Heppt, Markus V.
Kammerbauer, Claudia
Steeb, Theresa
Kirchner, Thomas
Flaig, Michael J.
French, Lars E.
Berking, Carola
Schmoeckel, Elisa
Reinholz, Markus
author_facet Wessely, Anja
Heppt, Markus V.
Kammerbauer, Claudia
Steeb, Theresa
Kirchner, Thomas
Flaig, Michael J.
French, Lars E.
Berking, Carola
Schmoeckel, Elisa
Reinholz, Markus
author_sort Wessely, Anja
collection PubMed
description SIMPLE SUMMARY: Anal squamous cell carcinoma (SCC) is a rare cancer often caused by infection with high-risk human papillomavirus (HPV). Immune checkpoint blockade (ICB) targeting PD-1 or PD-L1 is successfully used for the treatment of other cancers as melanoma and lung cancer and might be an option for anal SCC as well. PD-L1 expression is associated with ICB outcome for example in melanoma. Here, we investigated whether infection with HPV affects PD-L1 expression and observed that almost two-thirds of anal SCC patients had PD-L1 positive tumors. Interestingly, these patients had a better median overall survival (OS). Sex, grade of differentiation, and HPV infection status did not influence the median OS. HPV infection status and PD-L1 expression were not correlated. Our findings indicate that PD-L1 is an independent prognostic marker in anal SCC. Besides, ICB targeting PD-1 or PD-L1 might be a therapy option for anal SCC patients irrespective of HPV infection status. ABSTRACT: Anal squamous cell carcinoma (SCC) is a rare cancer with increasing incidence. Infection with high-risk human papillomavirus (HPV) subtypes is the major cause for its development. We retrospectively analyzed tumor samples from 54 anal SCC patients for infection with a panel of 32 HPV subtypes in a PCR-based approach, determined the PD-L1 expression status, and correlated the findings with the clinical data and the survival of the patients. Forty-two patients (77.8%) were HPV-positive and harbored at least one carcinogenic HPV subtype. HPV16 was the most frequently detected (n = 39, 72.2%). Four patients were infected with multiple HPV subtypes. HPV infection was significantly more often detected in female than in male patients (90.3% vs. 60.9%, p = 0.018). Patients with PD-L1 positive tumors showed a significantly better median overall survival (OS) compared with patients with PD-L1 negative tumors (69.3 vs. 28.3 months, p = 0.006). The median OS was significantly different among the distinct tumor stages (p = 0.029). Sex, grade of differentiation, and HPV infection status did not influence the median OS. Furthermore, HPV infection status and PD-L1 expression were not correlated. A multivariate Cox regression analysis revealed that PD-L1 expression status was an independent prognostic marker for survival (p = 0.012).
format Online
Article
Text
id pubmed-7564961
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75649612020-10-26 Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma Wessely, Anja Heppt, Markus V. Kammerbauer, Claudia Steeb, Theresa Kirchner, Thomas Flaig, Michael J. French, Lars E. Berking, Carola Schmoeckel, Elisa Reinholz, Markus Cancers (Basel) Article SIMPLE SUMMARY: Anal squamous cell carcinoma (SCC) is a rare cancer often caused by infection with high-risk human papillomavirus (HPV). Immune checkpoint blockade (ICB) targeting PD-1 or PD-L1 is successfully used for the treatment of other cancers as melanoma and lung cancer and might be an option for anal SCC as well. PD-L1 expression is associated with ICB outcome for example in melanoma. Here, we investigated whether infection with HPV affects PD-L1 expression and observed that almost two-thirds of anal SCC patients had PD-L1 positive tumors. Interestingly, these patients had a better median overall survival (OS). Sex, grade of differentiation, and HPV infection status did not influence the median OS. HPV infection status and PD-L1 expression were not correlated. Our findings indicate that PD-L1 is an independent prognostic marker in anal SCC. Besides, ICB targeting PD-1 or PD-L1 might be a therapy option for anal SCC patients irrespective of HPV infection status. ABSTRACT: Anal squamous cell carcinoma (SCC) is a rare cancer with increasing incidence. Infection with high-risk human papillomavirus (HPV) subtypes is the major cause for its development. We retrospectively analyzed tumor samples from 54 anal SCC patients for infection with a panel of 32 HPV subtypes in a PCR-based approach, determined the PD-L1 expression status, and correlated the findings with the clinical data and the survival of the patients. Forty-two patients (77.8%) were HPV-positive and harbored at least one carcinogenic HPV subtype. HPV16 was the most frequently detected (n = 39, 72.2%). Four patients were infected with multiple HPV subtypes. HPV infection was significantly more often detected in female than in male patients (90.3% vs. 60.9%, p = 0.018). Patients with PD-L1 positive tumors showed a significantly better median overall survival (OS) compared with patients with PD-L1 negative tumors (69.3 vs. 28.3 months, p = 0.006). The median OS was significantly different among the distinct tumor stages (p = 0.029). Sex, grade of differentiation, and HPV infection status did not influence the median OS. Furthermore, HPV infection status and PD-L1 expression were not correlated. A multivariate Cox regression analysis revealed that PD-L1 expression status was an independent prognostic marker for survival (p = 0.012). MDPI 2020-09-04 /pmc/articles/PMC7564961/ /pubmed/32899762 http://dx.doi.org/10.3390/cancers12092516 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wessely, Anja
Heppt, Markus V.
Kammerbauer, Claudia
Steeb, Theresa
Kirchner, Thomas
Flaig, Michael J.
French, Lars E.
Berking, Carola
Schmoeckel, Elisa
Reinholz, Markus
Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
title Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
title_full Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
title_fullStr Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
title_full_unstemmed Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
title_short Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma
title_sort evaluation of pd-l1 expression and hpv genotyping in anal squamous cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564961/
https://www.ncbi.nlm.nih.gov/pubmed/32899762
http://dx.doi.org/10.3390/cancers12092516
work_keys_str_mv AT wesselyanja evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT hepptmarkusv evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT kammerbauerclaudia evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT steebtheresa evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT kirchnerthomas evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT flaigmichaelj evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT frenchlarse evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT berkingcarola evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT schmoeckelelisa evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma
AT reinholzmarkus evaluationofpdl1expressionandhpvgenotypinginanalsquamouscellcarcinoma